§ Knowledge of the phase 2 interim clinical trial is expected in the fourth quarter of 21
§ Nature Neuroscience and Cell Reports publications highlight the complementary mechanisms of viral replication and immunosuppression of 3CLpro (Mpro)
New York, NY and Tel Aviv, ISRAELL, November 1, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and theranosis responses company, announced today that it is now adding Hillel Yaffe Medical Center as the 2d clinical trial site in Hadera, Israel, for its ongoing, randomized, double-blind, placebo-controlled Phase 2 tollovir® clinical trial for the COVID-19 inpatient remedy. 3CL Protease (3CLpro, Main Protease, MPro, Nsp5) antiviral/anti-cytokine cure candidate targeting protease blockade 3CL Shaare Zedek Medical Center in Jerusalem, Israel, was the first site opened in April 2021 that has recruited 30 patients to date. An independent review of interim knowledge of protection and efficacy through the Data Safety Monitoring Board (DSMB) of knowledge collected from randomized trials in the fourth quarter of 2021 is expected and will consult on next steps in program progression to burn the COVID-19 curative remedy.
“The addition of a momentary clinical trial site will increase enrollment in our ongoing Phase 2 randomized trial and will also expand Tollovir’s clinical footprint,” said Gerald Commissiong, president and CHIEF executive officer of Todos Medical. “Research of the next knowledge is quite vital as it will consult the next steps in our clinical progression route as we read about the prospective use of Tollovir beyond inpatients and prospectively compare its efficacy in moderate (pre-hospital) COVID and prolonged COVID in the future. “
“The recent functional validation of our long-standing studies on 3CLpro through two independent teams with publications on 3CLpro in Nature Neuroscience and Cell Reports actually provides solid results for the clinical outcomes we have observed in Israel since the beginning of the pandemic,” said Dr. Dorit Arad, Chief Scientific Officer of NLC Pharma, the partner of the company’s 3CL protease diagnostic and cure joint venture. “We are now comparing the implications of those effects for clinical progression from our upcoming phase 2 interim studies presented in moderate and long-distance COVID trials, as well as for pediatric populations that have very few features at this time. Since Tollovir is well tolerated, we see the possibility of helping young people suffering from COVID-19. »
About All Medical Ltd.
All Medical Ltd. (OTCQB: TOMDF), founded in Rehovot, Israel, with offices in New York, designs important diagnostic responses for the early detection of a variety of cancers. Detection generation that employs peripheral blood tests that display a comprehensive examination of the influence of cancer on the immune system, looking for biochemical adjustments in the mononuclear cells of blood and plasma. TMB-2, have won CE marking in Europe. Recently, it recently acquired the American medical diagnostics company Provista Diagnostics, Inc. to secure the rights of their qualified CLIA/CAP laboratory founded in Alpharetta, Georgia, which is lately acting with COVID PCR control and Provista’s Videssa. ® breast cancer blood tests at the advertising stage.
Everyone is also coming up with blood tests for the early detection of neurodegenerative diseases, such as Alzheimer’s disease. The LymPro Test ™ is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes for exogenous mitogenic stimulation that induces them to enter the mobile cycle. Some diseases, adding Alzheimer’s disease, are thought to be the result of compromised mobile machinery leading to aberrant re-entry of the mobile cycle through neurons, which then leads to apoptosis. in the use of peripheral blood lymphocytes as a replacement for neuronal mobile function, suggesting a non-unusual dating between PBL and neurons in the brain.
All have entered into distribution agreements with corporations to distribute safe verification kits for the novel coronavirus (COVID-19). The agreements cover several foreign suppliers of PCR verification kits and similar apparatus and materials, as well as multi-brand antibody verification kits after completing the validation of such verification kits and materials in their CLIA/CAP qualified spouse laboratory in the United States. In addition, Todos has entered into a joint venture with NLC Pharma to further expand 3CL protease diagnostic controls, as well as 3CL protease inhibitors that target a basic reproductive mechanism of coronaviruses.
For more information, https://www. todosmedical. com/.
Forward-Looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our clinical progression systems and expected clinical trials. These forward-looking statements are based only on management’s existing expectations and are subject to significant dangers and uncertainties that may also cause actual effects to differ materially from those described in the forward-looking statements, adding hazards and uncertainties related to progress. timing, burden, and effects of clinical trials and product progression systems; difficulties or delays in obtaining regulatory approval or patent coverage for candidate products; festival of other biogeneration companies; and our ability to secure the additional investment required to carry out our research, progression and commercialization activities. In addition, the following factors, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments in generation requirements and market place; delays or obstacles in starting our clinical trials; adjustments in legislation; the ability to expand and introduce new technologies, products, and programs in a timely manner; the lack of validation of our generation as we move forward and the lack of acceptance of our strategies throughout the clinical community; not retaining or attracting key workers whose wisdom is essential to the progression of our products; unforeseen clinical difficulties that could possibly expand with our process; a load of the final product higher than expected; loss of market place percentage and value stress as a result of the festival; and laboratory effects that do not translate into equally intelligent effects under actual conditions, which may also cause actual effects or functionality to differ materially from those considered in such forward-looking statements. Unless otherwise provided by law, Todos Medical does not adopt to publish revisions to those forward-looking statements to reflect occasions or events after the date hereof or to reflect the occurrence of unforeseen occasions. For a more detailed description of the hazards and uncertainties affecting Todos Medical, please refer to its periodic reports with the United States Securities and Exchange Commission.
Contact companies and investors:
Richard Galterio
Medical back
732-642-7770
rich. g@todosmedical. com